FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115705087> ?p ?o ?g. }

• W2115705087 endingPage "9" @default.
• W2115705087 startingPage "1" @default.
• W2115705087 abstract "Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population. We assessed changes in spleen size and constitutional symptoms during ruxolitinib treatment using a retrospective, observational review of anonymized US medical record data of patients diagnosed with IPSS low-risk (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>25</mml:mn></mml:math>) or intermediate-1-risk (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M2><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>83</mml:mn></mml:math>) MF. The majority of patients were male (low risk, 60%; intermediate-1 risk, 69%). Most patients (92% and 77%) were still receiving ruxolitinib at the medical record abstraction date (median observation/exposure time, 8 months). The proportion of patients with moderate or severe palpable splenomegaly (≥10 cm) decreased from diagnosis (56%) to best response (12%). Fatigue was reported in 47% of patients and was the most common constitutional symptom. For most symptoms in both risk groups, shifts in the distribution of severity from more to less severe from diagnosis to best response were observed. Both patients with low-risk and intermediate-1-risk MF experienced a substantial decrease in spleen size with ruxolitinib treatment in real-world settings. For most symptoms examined, there were distinct improvements in the distribution of severity during ruxolitinib treatment. These findings suggest that patients with lower-risk MF may benefit clinically from ruxolitinib treatment." @default.
• W2115705087 created "2016-06-24" @default.
• W2115705087 creator A5000505169 @default.
• W2115705087 creator A5057922236 @default.
• W2115705087 creator A5058952186 @default.
• W2115705087 creator A5066934430 @default.
• W2115705087 creator A5069970576 @default.
• W2115705087 creator A5087962548 @default.
• W2115705087 date "2015-01-01" @default.
• W2115705087 modified "2023-10-02" @default.
• W2115705087 title "Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib" @default.
• W2115705087 cites W135049235 @default.
• W2115705087 cites W1545484310 @default.
• W2115705087 cites W1552752443 @default.
• W2115705087 cites W1980568348 @default.
• W2115705087 cites W1981098678 @default.
• W2115705087 cites W1987159900 @default.
• W2115705087 cites W1991495650 @default.
• W2115705087 cites W2023311627 @default.
• W2115705087 cites W2049965335 @default.
• W2115705087 cites W2057360098 @default.
• W2115705087 cites W2093158866 @default.
• W2115705087 cites W2100293053 @default.
• W2115705087 cites W2115351357 @default.
• W2115705087 cites W2118776994 @default.
• W2115705087 cites W2121743767 @default.
• W2115705087 cites W2126532431 @default.
• W2115705087 cites W2127559749 @default.
• W2115705087 cites W2133633030 @default.
• W2115705087 cites W2143057570 @default.
• W2115705087 cites W2144664431 @default.
• W2115705087 cites W2149055075 @default.
• W2115705087 cites W2154558042 @default.
• W2115705087 cites W2156484880 @default.
• W2115705087 cites W2160219845 @default.
• W2115705087 doi "https://doi.org/10.1155/2015/848473" @default.
• W2115705087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4655278" @default.
• W2115705087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26635878" @default.
• W2115705087 hasPublicationYear "2015" @default.
• W2115705087 type Work @default.
• W2115705087 sameAs 2115705087 @default.
• W2115705087 citedByCount "21" @default.
• W2115705087 countsByYear W21157050872016 @default.
• W2115705087 countsByYear W21157050872017 @default.
• W2115705087 countsByYear W21157050872018 @default.
• W2115705087 countsByYear W21157050872019 @default.
• W2115705087 countsByYear W21157050872020 @default.
• W2115705087 countsByYear W21157050872021 @default.
• W2115705087 countsByYear W21157050872022 @default.
• W2115705087 countsByYear W21157050872023 @default.
• W2115705087 crossrefType "journal-article" @default.
• W2115705087 hasAuthorship W2115705087A5000505169 @default.
• W2115705087 hasAuthorship W2115705087A5057922236 @default.
• W2115705087 hasAuthorship W2115705087A5058952186 @default.
• W2115705087 hasAuthorship W2115705087A5066934430 @default.
• W2115705087 hasAuthorship W2115705087A5069970576 @default.
• W2115705087 hasAuthorship W2115705087A5087962548 @default.
• W2115705087 hasBestOaLocation W21157050871 @default.
• W2115705087 hasConcept C11413529 @default.
• W2115705087 hasConcept C126322002 @default.
• W2115705087 hasConcept C167135981 @default.
• W2115705087 hasConcept C195910791 @default.
• W2115705087 hasConcept C2776112149 @default.
• W2115705087 hasConcept C2777753580 @default.
• W2115705087 hasConcept C2779134260 @default.
• W2115705087 hasConcept C2780007613 @default.
• W2115705087 hasConcept C2780076729 @default.
• W2115705087 hasConcept C2908647359 @default.
• W2115705087 hasConcept C41008148 @default.
• W2115705087 hasConcept C71924100 @default.
• W2115705087 hasConcept C99454951 @default.
• W2115705087 hasConceptScore W2115705087C11413529 @default.
• W2115705087 hasConceptScore W2115705087C126322002 @default.
• W2115705087 hasConceptScore W2115705087C167135981 @default.
• W2115705087 hasConceptScore W2115705087C195910791 @default.
• W2115705087 hasConceptScore W2115705087C2776112149 @default.
• W2115705087 hasConceptScore W2115705087C2777753580 @default.
• W2115705087 hasConceptScore W2115705087C2779134260 @default.
• W2115705087 hasConceptScore W2115705087C2780007613 @default.
• W2115705087 hasConceptScore W2115705087C2780076729 @default.
• W2115705087 hasConceptScore W2115705087C2908647359 @default.
• W2115705087 hasConceptScore W2115705087C41008148 @default.
• W2115705087 hasConceptScore W2115705087C71924100 @default.
• W2115705087 hasConceptScore W2115705087C99454951 @default.
• W2115705087 hasLocation W21157050871 @default.
• W2115705087 hasLocation W21157050872 @default.
• W2115705087 hasLocation W21157050873 @default.
• W2115705087 hasLocation W21157050874 @default.
• W2115705087 hasOpenAccess W2115705087 @default.
• W2115705087 hasPrimaryLocation W21157050871 @default.
• W2115705087 hasRelatedWork W1869576177 @default.
• W2115705087 hasRelatedWork W1883475886 @default.
• W2115705087 hasRelatedWork W1959609799 @default.
• W2115705087 hasRelatedWork W2077076503 @default.
• W2115705087 hasRelatedWork W2143057570 @default.
• W2115705087 hasRelatedWork W2304558087 @default.
• W2115705087 hasRelatedWork W2805747764 @default.
• W2115705087 hasRelatedWork W2810060832 @default.

• next